(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) on Friday announced that preliminary unaudited total revenue in the fourth quarter of 2024 was $130.8 million, up 40 percent from the prior year, and preliminary unaudited total revenue for full year 2024 was $450 million, up 36 percent from the previous year.
Meanwhile, preliminary ORLADEYO net revenue was $437 million for the full year 2024, up 34 percent from last year, whereas the same for the fourth quarter rose 36 percent to $123.5 million.
Looking ahead, the company anticipates full year 2025 global net ORLADEYO revenue of $515 million to $535 million, and total revenue (including RAPIVAB) is expected to be between $540 million to $560 million.
Additionally, it sees full year 2025 total revenue (including RAPIVAB (peramivir injection)) to be between $540 million and $560 million.
The company further added that it expects to approach quarterly positive EPS and positive cash flow in the second half of 2025, and to be profitable on an EPS basis, with positive cash flow, for full year 2026.
In the pre-market hours, BioCryst's stock is trading at $8.10, up 0.62 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
